Warp why can't you just admit the fact that GC is not sticking to the script of 2012 or 2013! He keeps changing his mind! And by changing his mind I mean strengthening and expanding the company!

It is interesting that we announce it today with Roman Urfer speaking.

Presenter: Roman Urfer, Ph.D., Chief Development Officer at NeuroAssets

Also from NeruroAssets

NeuroAssets’ team is led by David A. Lowe PhD,
http://www.neuroassets.com

Quote:

---

"I'm extremely pleased with the addition of DioGenix to Amarantus' emerging neurodiagnostics business unit," said David A. Lowe, Ph.D., member of the Amarantus Board Directors . "Improving the standard of diagnosis for MS is of critical need for patients and physicians. The data generated in the clinical validation study clearly demonstrates that MSPrecise can play a vital role in improving the outcomes for patients more rapidly versus today's current standard alone. The addition of next generation sequencing to our current stable of platforms also brings in tremendous know-how to our diagnostic unit that will in turn strengthen the company's base as we prepare to establish a standalone neurodiagnostic corporate entity."

---

Cheers!!!